Reuters logo
BRIEF-Beigene presents updated clinical data on BTK Inhibitor BGB-3111 in CLL, SLL patients
December 5, 2016 / 4:36 PM / a year ago

BRIEF-Beigene presents updated clinical data on BTK Inhibitor BGB-3111 in CLL, SLL patients

Dec 5 (Reuters) - Beigene Ltd :

* Beigene presents updated clinical data on BTK Inhibitor BGB-3111 in patients with chronic lymphocytic leukemia and small lymphocytic leukemia at the 2016 American Society Of Hematology Annual Meeting

* preliminary clinical data demonstrate that BGB-3111 is well-tolerated and highly active in CLL / SLL, with an overall response rate of 96%

* only one patient to date has discontinued BGB-3111 treatment for an adverse event, a grade 2 pleural effusion

* three serious AES (SAES) were assessed as possibly related to BGB-3111 in Phase 1 study

* no instances of disease progression or Richter’s transformation have occurred Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below